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Aims: Chronic heart failure may lead to chronic kidney disease. Previous studies sug-
gest tubular markers N-acetyl-b-D-glucosaminidase (NAG) and Kidney-injury-
molecule-1 (KIM-1) as potential markers for the cardiorenal syndrome (CRS). The
prognostic value of NAG and KIM-1 regarding implantable cardioverter defibrillator
(ICD) shock therapies is unknown.
Methods: We included 314 patients with an ICD and collected plasma and urine sam-
ples. Urine-values of NAG and KIM-1 got related to urinary creatinine. Outcomes of
interest were sustained adequate shock therapies and a combined endpoint of all-
cause mortality, rehospitalisation due to congestive heart failure and adequate shock
therapies. Follow up time was 32 months (IQR 6-35 months).
Results: KIM-1 and NAG were positively correlated with NT-proBNP (KIM-1: r = .34,
P < .001; NAG: r = .47, P < .001). NAG was significantly elevated in patients with pri-
mary prevention compared with secondary prevention ICD indication (P = .003).
According to Kaplan Meier analysis, NAG as well as NT-proBNP were significant pre-
dictors for adequate ICD shock therapies and for the combined endpoint (each
P < .001). Elevated KIM-1 showed no significant differences (each P = n.s.). In multi-
variate cox regression analysis, NAG as well as NT-proBNP were both independent
predictors for adequate ICD shock therapies as well as the combined endpoint,
beside ejection fraction <35% (each P < .05). Diabetes, primary prevention ICD indi-
cation, coronary artery disease, eGFR and age were no significant predictors for both
endpoints (each P = n.s.).
Conclusion: Similar to NT-proBNP, NAG showed promising value for overall prog-
nostication in ICD patients. Especially, NAG seems to incorporate an additional prog-
nostic value regarding occurrence of ICD shock therapies.
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Chronic heart failure (CHF) is one of the main causes of death and
presents a global public health problem.1 Ventricular arrhythmias with
consecutive Sudden Cardiac Death are potential outcomes of CHF
and present a major cause for mortality.1-3 For diagnosis of CHF,
plasma NT-proBNP represents the gold standard.4 Further, chronic
kidney disease is often concomitant in CHF. The coexistence of car-
dial and renal dysfunction is described as cardiorenal syndrome
(CRS).5 In regard to diagnosis of CRS, tubular markers were studied to
detect renal impairment in heart failure.6-8 Originally, urinary KIM-19
and urinary NAG10 as markers of tubular damage were investigated in
acute kidney injury11 then with reference to diagnosis and clinical out-
come of CRS type 2, which describes chronic renal impairment based
on CHF.12 So far, KIM-1 and NAG were investigated mainly for prog-
nostication of all-cause mortality and rehospitalisation due to conges-
tive heart failure.7,13
However, it is unknown whether tubular markers can also predict
clinical outcome regarding occurrence of ventricular arrhythmias.
Prognostication of ventricular arrhythmias and Sudden Cardiac Death
is a challenge so far. To identify high-risk patients, new biomarkers are
required.3 This is important, as especially high-risk patients may bene-
fit from primary preventive implantable cardioverter defibrillator (ICD)
implantation.14 Further, ICD patients suffering from proceeding or
advanced CRS may profit from a closer and more frequent surveil-
lance. Aim of the current study was to assess if NAG, KIM-1 as well as
NT-proBNP provide additional value regarding prognosis of ventricu-
lar arrhythmias and Sudden Cardiac Death. Therefore, we analysed a
large cohort of ICD patients regarding occurrence of adequate ICD
shock therapies.
1 | METHODS
1.1 | Study population
Between October 2015 and April 2016 and between April 2018 and
October 2018, a total of 314 patients with an ICD implanted at the
university hospital of Regensburg were included in the study. Included
were all patients with an ICD above 18 years who were treated in our
out-patient clinic and who were able to sign the consent form. Exclu-
sion criteria were severe chronic kidney disease (KDIGO eGFR cate-
gory 5),15 patients receiving hospital treatment due to acute cardiac
or acute renal deterioration as well as all patients with CRT-P aggre-
gates. Patients were included independent of primary or secondary
prevention ICD indication. Indication for ICD implantation was
according to specific ESC guidelines. Primary preventive ICD implan-
tation was indicated in patients with severely reduced left ventricular
ejection fraction and a failed trial of optimal medical therapy to
increase the left ventricular ejection fraction to >35% accompanied by
increased risk of Sudden Cardiac Death.16 Secondary preventive ICD
implantation was indicated in patients with documented ventricular
fibrillation, haemodynamically not tolerated ventricular tachycardia or
reanimated Sudden Cardiac Death due to malignant ventricular
arrhythmias in the absence of reversible causes.2 CKD was defined
analogous to the Kidney Disease: Improving Global Outcomes
(KDIGO) guidelines as kidney damage (structural or functional abnor-
malities of the kidneys) for longer than 3 months, with or without
decreased eGFR, or as declined kidney function with eGFR
<60 mL/min per 1.73 m2 for longer than 3 months, with or without
structural or functional abnormalities of the kidneys.15 In order to
define CKD regarding KDIGO guidelines previous values of serum cre-
atinine and eGFR were obtained from all patients.
Each patient was interviewed (New York Heart Association
[NYHA] stage, drug therapy, pre-existing illnesses) and physically
examined (weight, oedema, pulmonary rates, elevated jugular venous
pressure). Ejection fraction (EF) was evaluated by echocardiography
according to Simpsons's method. Estimated glomerular filtration rate
(eGFR) was calculated according to the CKD-EPI formula.17
As endpoints were used occurrence of adequate ICD shock thera-
pies as well as a combined endpoint of all-cause mortality and
rehospitalisation due to congestive heart failure as well as adequate
ICD shock therapies. Ventricular arrhythmias receiving antitachycardia
pacing therapies without shock therapy were not included. A follow
up was performed up to April 2019, by telephone interviews and eval-
uation of hospital medical files, especially analysis of reports of ICD
interrogations. Date of death was confirmed by hospital or death reg-
istries or by relatives.
The institutional ethics committee permitted an execution of this
study. It was performed in agreement with good clinical practice
guidelines and with the standards established for human experimenta-
tion by the Declaration of Helsinki.
2 | SAMPLE COLLECTION AND
BIOCHEMICAL ANALYSES
At enrolment, blood and urine samples were collected on the same
day. All patients were scheduled in the morning. Venepuncture was
performed immediately after patient arrival in our outpatient clinic.
Urine samples were collected by each patient from first-morning spot
urine into prepared and in advance to the patient mailed sterile cups.
Blood and urine samples were immediately sent to the central labora-
tory and NT-proBNP, serum as well as urinary creatinine (enzymatic)
were immediately analysed on a Dimension Vista 1500 auto analyser
(Siemens Healthineers). Serum creatinine was measured by enzymatic
methods and Siemens test “ECREA.” For analysis of the tubular
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associated with clinically important outcomes including
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markers KIM-1 and NAG urine samples were aliquoted into 2 mL
tubes and stored at −80C. They were thawed directly before analy-
sis. KIM-1 was measured with the KIM-1 ELISA Duo kit and the
respective ancillary reagent kit (#DY1750B and #DY008, R&D Sys-
tems) according to the manufacturer's instructions. The NAG assay
was performed with a modified protocol in 96 well plates
(#10875406001, Roche Diagnostics). In brief 100 μL of substrate
solution were used per well and pre-incubated for 5 minutes at 37C.
Then, 5 μL of sample, control or standard was added to the plate and
shaken for 30 seconds. After an incubation for 60 minutes at 37C,
the reaction was stopped by the addition of 200 μL of stop solution
followed by a final incubation for 10 minutes at 37C. Absorbance
was read at 580 nm. The standard curve was determined with
undiluted, 1:2, 1:5, 1:7.5 and 1:10 diluted Roche standard solution.
KIM-1 and NAG were normalized to urinary creatinine to compensate
the influence of variable urinary concentration on concentration of
urinary biomarkers. Normalization to urinary creatinine is the standard
method used for spot urine parameters in clinical trials.18
3 | STATISTICS
Descriptive data are presented as mean (±SD) for normally distributed
data or medians and IQR for non-normally distributed data. Correla-
tion coefficients were estimated according to Spearman. Normally
distributed values were evaluated with Student's unpaired two-sided
t-test. Non-normally distributed variables were evaluated with the
Mann-Whitney-U test. Boxplots were performed to analyse and visu-
alize the differences in marker concentrations between patients with
coronary artery disease and dilatative cardiomyopathy as well as
channelopathy. The receiver operating curves (ROC) were calculated
and the area under the curves (AUC) and 95% confidence intervals
were estimated. For a follow-up analysis, we constructed Kaplan
Meier survival curves reflecting the relationship between the probabil-
ity of reaching the endpoints and time of follow-up. Median values
were used as the binary cutpoints for KIM-1 (877.63 ng/g crea), NAG
(2.43 U/g crea) and NT-proBNP (800.00 pg/mL). Mean follow-up time
was 32 months (IQR 6-35 months). Multivariate cox proportional
TABLE 1 Baseline characteristics
All (n = 314) NAG < median (n = 157) NAG ≥ median (n = 157) P-values
Age (years) 61.7 (±14.8) 58.1 (±15.8) 65.4 (±12.9) <.001
Male 265 (84.4%) 135 (86.0%) 130 (82.8%) .44
Body mass index (kg/m2) 28.69 (±5.64) 28.3 (±5.0) 29.1 (±6.2) .61
Primary prevention ICD indication 143 (45.5%) 59 (37.6%) 84 (53.5%) <.01
CRT-D 73 (23.2%) 31 (19.7%) 42 (26.8%) .15
Coronary artery disease 142 (45.2%) 67 (42.7%) 75 (47.8%) .14
DCM 76 (24.2%) 32 (20.4%) 44 (28.0%) .11
Othersa 96 (30.6%) 58 (36.8%) 38 (24.2%) .04
Hypertension 191 (60.8%) 85 (54.1%) 106 (67.5%) .02
Diabetes 72 (22.9%) 23 (14.6%) 49 (31.2%) <.001
EF (%) 44 (IQR 34-55) 50 (IQR 38-58) 40 (IQR 31-50) <.001
<35% 86 (27.4%) 32 (20.4%) 54 (34.3%) <.01
CKD 128 (40.7%) 41 (26.1%) 87 (55.4%) <.001
eGFR (mL/min per 1,73m2)
≥60 201 (64.0%) 119 (75.8%) 82 (52.2%) <.001
45-59 51 (16.2%) 19 (12.1%) 32 (20.4%) .07
30-44 50 (15.9%) 17 (10.8%) 33 (21.0%) .01
15-29 12 (3.8%) 2 (1.3%) 10 (6.4%) .02
Drug therapy
ACE-I/ARB/ARNI 245 (83.4%) 116 (73.9%) 129 (82.2%) .08
Aldosteron-Antagonist 165 (52.5%) 76 (48.4%) 89 (56.7%) .14
Beta-Blocker 282 (89.8%) 133 (84.7%) 149 (94.9%) <.01
Digitalis 34 (10.8%) 8 (53.3%) 26 (16.6%) <.01
Calcium channel blocker 28 (8.9%) 13 (8.3%) 15 (9.5%) .70
Diuretic 207 (65.9%) 84 (53.5%) 123 (78.3%) <.001
KIM-1 (ng/g crea) 877.63 (IQR 555.98-1309.82) 694.69 (IQR 464.87-991.74) 1095.40 (IQR 730.22-1683.82) <.001
NAG (U/g crea) 2.43 (IQR 1.48-3.94)
NT-proBNP (pg/mL) 800.00 (IQR 263.00-2170.75) 402.00 (IQR 158.00-1094.50) 1345.00 (IQR 554.00-3125.50) <.001
aothers: secondary cardiomyopathy: 29 (9.2%), primary VF: 22 (7.0%), H(O)CM: 20 (6.4%), Brugada: 7 (2.2%), long-QT: 6 (1.9%), ARVD: 5 (1.6%), congenital
heart defect: 2 (0.6%), TakoTsubo: 2 (0.6%), Non-compaction cardiomyopathy: 1 (0.3%), muscular dystrophy: 1 (0.3%), short-QT: 1 (0.3%).
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hazard analysis was performed as stepwise regressions with backward
elimination to evaluate prognostic value of each marker regarding the
endpoints. Hereby we analysed NAG as well as NT-proBNP in cox
regression model with clinically relevant covariates for both endpoints
(eGFR, severely reduced EF, age, diabetes, coronary artery disease,
primary prevention ICD indication). Commercially available statistical
software packages were used for analysis (IBM SPSS statistics
25, SPSS INC., Chicago, Illinois; MedCalc 19.4.1, MedCalc Software
Ltd, Ostend, Belgium).
4 | RESULTS
4.1 | Study population
Baseline characteristics are presented in Table 1. Mean age was
62 years and the majority of patients were men. About half of the
patients had a secondary prevention indication for ICD implantation.
Coronary artery disease was present in about half of the patients and
DCM in about a quarter of the patients. Less than half of the patients
were suffering from CKD. Severely reduced left ventricular function
(EF <35%) was present in less than one-third of the patients.
4.2 | Tubular biomarkers in ICD patients
KIM-1 and NAG were significantly negatively correlated with Crea
eGFR (r = −.16 as well as r = −.37, each P < .001), CystatinC eGFR
(r = −.27 as well as r = −.50, each P < .001) and EF (r = −.17 as well as
r = −.30, each P < .001).
KIM-1 and NAG were significantly positively correlated with NT-
proBNP (r = .34 as well as r = .47, each P < .001) and NYHA stage
(r = .27 as well as r = .28, each P < .001).
Each Marker was correlated with CKD stage (NT-proBNP:
r = .482, P < .001; NAG: r = .347, P < .001; KIM-1: r = .11, P = .04).
About one third of patients had an eGFR lower than 60 mL/min per
1.73m2. eGFR lower than 30 mL/min per 1.73m2 was present in
12 patients. Marker levels were significantly elevated in patients with
initial CKD (each P < .02, Table 2). There were no relevant
associations of KIM-1 and NAG levels according to CKD stages
(Figure 1). Patients with primary prevention ICD indication showed
higher concentrations of NAG (P = .003) and NT-proBNP (P = .001,
Table 2) than patients with secondary prevention ICD indication,
opposite to KIM-1 (P = n.s.). KIM-1, NAG and NT-proBNP were signif-
icantly elevated in severely symptomatic patients defined by NHYA
stage ≥3 as well as in patients with reduced ejection fraction <35%
(each P < .05, Table 2). Further, KIM-1, NAG and NT-proBNP were
significantly elevated in patients suffering from ICM as well as DCM
compared with Channelopathy (each P < .01, Figure 2). No marker
showed significant differences between ICM and DCM (each P = n.s.).
NAG, KIM-1 as well as NT-proBNP were significantly elevated in
deceased patients (each P < .001). NAG as well as NT-proBNP were
significantly increased in patients with sustained adequate shock ther-
apies during follow up (each P < .05), but not KIM-1 (P = n.s.). There
was no association between marker levels and occurrence of ICD
therapies by antitachycardia pacing without shock (each P = n.s.).
4.3 | Prognostication for shock therapy and
combined endpoint
The average follow-up period was 32 months (IQR 6-35 months).
During follow-up 37 (11.7%) patients died, 27 (8,6%) patients suffered
from adequate shock therapies and 34 (10.8%) patients were
rehospitalized due to congestive heart failure. Overall, 72 (22.9%)
patients reached the combined endpoint.
Regarding adequate shock therapy, ROC analysis for NT-proBNP
showed a higher AUC (0.70) than NAG (AUC: 0.64, Figure 3), but
there was no significant difference evident between AUCs of both
markers (P = n.s.). Regarding mortality, similar results could be
obtained with also no significant difference between AUCs of NT-
proBNP and NAG (NT-proBNP; AUC: 0.79 vs NAG; AUC: 0.70;
P = n.s.; Figure 3).
According to Kaplan Meier analysis, patients with NAG ≥ median
(2.43 U/g crea) had a higher rate of adequate shock therapies than
patients with NAG < median (20/157 (12.7%) vs 7/157 (4.5%);
P = .006, Figure 4). Higher NT-proBNP-levels (≥800.00 pg/mL) were
associated with a higher rate of adequate shock therapies (19/157
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(12.1%) vs 8/157 (5.1%); P = .036, Figure 4). KIM-1 ≥ median
(877.63 ng/g crea) was not associated with a higher rate of adequate
shock therapies according to Kaplan Meier analysis (P = n.s.).
NAG ≥ median as well as NT-proBNP ≥ median were significant
predictors for the combined endpoint (NAG: 51/157 (32.5%) vs
21/157 (13.3%); P < .001; NT-proBNP: 58/157 (36.9%) vs 14/157
(8.9%); P < .001, Figure 5), opposite to KIM-1 ≥ median (P = n.s.).
According to Cox regression analysis, NAG as well as NT-proBNP
were both independent predictors for adequate shock therapy as well
as the combined endpoint, beside severely reduced ejection fraction
(each P < .05, Tables 3 and 4). Diabetes, primary prevention ICD indi-
cation, coronary artery disease, age and eGFR were no significant pre-
dictors for both endpoints (each P = n.s.).
5 | DISCUSSION
In the current study, we evaluated the tubular markers NAG and
KIM-1 regarding their capacity to predict occurrence of ventricular
arrhythmias and adequate ICD shock therapies. Therefore, tubular
markers as well as NT-proBNP as an established marker for heart fail-
ure were investigated in a mixed cohort of patients with ICD. Espe-
cially NAG showed prognostic capabilities regarding occurrence of
adequate shock therapies similar to NT-proBNP. For antitachycardia
pacing without shock therapy no association with a marker could be
shown. NAG and NT-proBNP seem to incorporate predictive value
regarding fast ventricular tachycardias and ventricular fibrillation,
but not regarding monomorphic slow ventricular tachycardias.
F IGURE 1 Boxplots: Marker levels of KIM-1 and NAG according to CKD stage (#: P = .023 vs eGFR 45-59 mL/min per 1.73m2, §: P = .013 vs
eGFR 45-59 mL/min per 1.732, all others: each P = n.s.)
F IGURE 2 Boxplots: Marker levels of NT-proBNP, KIM-1 and NAG in patients suffering from ICM vs DCM vs Channelopathy
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Furthermore, NAG and NT-proBNP were independent predictors for
a combined endpoint, composed of all-cause mortality, adequate
shock therapies and rehospitalisation due to congestive heart failure.
The prognostic power of NAG and NT-proBNP regarding detection of
shock therapy as well as detection of mortality seem to be similar. No
significant difference could be shown in ROC analysis. Nevertheless,
there was a trend to higher AUCs regarding the established heart fail-
ure marker NT-proBNP. The association of NAG as a renal marker
F IGURE 3 Left: Receiver
operating characteristic analysis
for shock therapy in the overall
cohort; area under the curves
(AUC) of NT-proBNP and NAG in
regard to occurrence of shock
therapy. NT-proBNP; AUC: 0.70
vs NAG; AUC: 0.64, P = n.s..
Right: Receiver operating
characteristic analysis for
mortality in the overall cohort;
area under the curves (AUC) of
NT-proBNP and NAG in regard
to occurrence of mortality. NT-
proBNP; AUC: 0.79 vs NAG;
AUC: 0.70, P = n.s.
F IGURE 4 NT-proBNP and NAG: Kaplan Meier curves regarding shock therapy. Left: , NT-proBNP ≥800.00 pg/mL; NT-proBNP
<800.00 pg/mL; Right: , NAG ≥2.43 U/g crea; NAG <2.43 U/g crea
F IGURE 5 NT-proBNP and NAG: Kaplan Meier curves regarding the combined endpoint. Left: , NT-proBNP ≥800.00 pg/mL; NT-
proBNP <800.00 pg/mL; Right: , NAG ≥2.43 U/g crea; NAG <2.43 U/g crea
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with cardiac arrhythmias provides new benefit and confirms the role
of NAG as marker of cardiorenal syndrome. KIM-1 as well as kidney
function estimated by eGFR correlated to NAG and NT-proBNP, but
were not associated with adequate shock therapies in a mean follow-
up time of 32 months.
5.1 | Prognostication of tubular and cardial
markers
To our knowledge, the current study is the first one to evaluate candi-
date tubular biomarkers NAG and KIM-1 regarding their prognostic
capacity for ventricular arrhythmias in patients with ICD. Therefore,
our findings of NAG as an independent predictor for ventricular
arrhythmias provide potentially an additional value regarding risk eval-
uation of ventricular arrhythmias in heart failure. Damman et al
assessed in a large cohort the clinical outcome of CHF patients, mea-
sured by mortality and rehospitalisation and reported similar results.
Opposite to the current study, they did not investigate adequate ICD
shock therapies.13
In contrast to KIM-1, NAG could be shown as an independent
predictor for our combined endpoint. In accordance to Jungbauer
et al, NAG and KIM-1 were also shown as an independent predictor
for a combined endpoint of all-cause mortality and rehospitalisation
due to congestive heart failure (data not shown).7 The mean follow-up
time was about 52 months, while the current study had a mean
follow-up time of 32 months and investigated also adequate ICD
shock therapies.
Consistent with our findings of association between NT-proBNP
and adequate shock therapies, Levine et al also reported increased
levels of NT-proBNP as predictor for ventricular arrhythmias in a
cohort of only primary prevention ICD indication19 whereas Klein
et al could not show an association between NT-proBNP and occur-
rence of ventricular arrhythmias.20 The latter cohort included almost
solely patients with secondary prevention ICD indication and the
mean follow up time was about half as long as in the current study.
Therefore, direct comparisons seem not to be feasible. Simsek et al
could show associations between NT-proBNP and mortality.21 In the
current study, NT-proBNP is associated with the combined endpoint
consisting of mortality, adequate shock therapies and rehospitalisation
due to congestive heart failure. NT-proBNP is an established marker
for heart failure, which is associated with mortality and hospitaliza-
tion.4,22 Thereby, our findings are conform. According to available
data, NT-proBNP seems not only to be a marker for heart failure, but
also to be relevant in risk stratification for ventricular arrhythmias.
Decreasing systolic heart function, volume overload and sequentially
myocardial stretching are the main trigger for secretion of NT-proBNP
and a risk factor for increased vulnerability for arrhythmias.23-25
5.2 | Association between NAG and ventricular
arrhythmias
Cardial and renal function are strongly dependent and coexistence of
cardial and renal dysfunction is described as cardiorenal syndrome.
Worsening of one causes worsening of the other.26 Pathophysiologi-
cal aspects are not fully understood. Hypoperfusion and neurohor-
monal abnormalities are predominantly discussed.12 Tubular
impairment leads to secretion of NAG and KIM-1 in the urine.9,10
They can already be measured without decline of glomerular filtration
TABLE 3 NAG and NT-proBNP: Cox regression analysis regarding shock therapy
Risk factors NAG P-value HR 95% CI NT-proBNP/100 P-value HR 95% CI
Marker .01 1.058 1.013-1.105 <.01 1.005 1.002-1.009
Severely reduced EF (<35%) .01 2.841 1.244-6.485 <.05 2.422 1.022-5.742
Coronary artery disease .12 0.479 0.191-1.204 .15 0.506 0.201-1.275
Primary prevention ICD indication .15 0.529 0.224-1.247 .18 0.555 0.234-1.316
Age .34 0.984 0.952-1.017 .20 0.978 0.946-1.012
eGFR .58 0.994 0.974-1.015 .48 0.992 0.971-1.014
Diabetes .51 0.681 0.217-2.136 .56 0.713 0.226-2.250
TABLE 4 NAG and NT-proBNP: Cox regression analysis regarding the combined endpoint
Risk factors NAG P-value HR 95% CI NT-proBNP/100 P-value HR 95% CI
Marker <.01 1.062 1.029-1.095 <.01 1.006 1.003-1.008
Severely reduced EF (<35%) <.01 2.123 1.291-3.491 .02 1.867 1.118-3.120
Coronary artery disease .57 1.157 0.697-1.921 .46 1.210 0.728-2.009
Primary prevention ICD indication .51 1.183 0.721-1.939 .47 1.203 0.733-1.976
Age .74 1.004 0.981-1.028 .90 0.998 0.975-1.022
eGFR .08 0.989 0.976-1.001 .07 0.988 0.975-1.001
Diabetes .13 0.638 0.355-1.144 .21 0.687 0.381-1.240
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rate and with preserved renal function.27 The capability of tubular
markers NAG and KIM-1 to identify subclinical renal impairment in
patients with CHF affirm their usefulness as cardiorenal markers.6,8
Elevated values of NAG and KIM-1 are indicators of a proceeding
CRS.8 Worsening heart function accompanies higher risk for
arrhythmogen events and mortality.28,29 In the current study, NAG
seemed to incorporate prognostic value regarding ventricular arrhyth-
mias, opposite to KIM-1.
Accordingly, the current results confirm the transition from AKI
diagnosis markers to markers of CRS.8 Additionally, the results sug-
gest to extend the prognostic value of tubular markers regarding risk
stratification for arrhythmogen events in CHF. The potential useful-
ness of tubular markers to predict cardial outcome verifies the impor-
tance and dependence on renal function in patients with CHF.
Worsening renal function may lead to electrolyte shifting and espe-
cially deviant potassium serum concentrations are associated with
arrthymogen events.30 To confirm this hypothesis, more investiga-
tions are necessary.
5.3 | Utilization in clinical practice
Potentially, NT-proBNP as well as NAG may contribute to identify
patients with high-risk for ventricular arrhythmias and Sudden Cardiac
Death. Patients with ICD and proceeding or advanced CRS measured
by tubular markers may benefit from closer and more frequent surveil-
lance. Periodical measurements of electrolytes, especially of potas-
sium as well as targeted handling of antiarrhythmic drugs as well as
optimized ICD adjustments may be useful in treatment of these
patients. Potentially, reaching the endpoints (shock therapies,
rehospitalisation, mortality) can be avoided or delayed by improved,
well-timed and adapted treatment of CRS in high-risk patients. More-
over, NAG and NT-proBNP may contribute to differentiate patients,
who will profit from ICD implantation. On the one hand, Sudden Car-
diac Death is a major public health problem and preventive ICD-
implantation can reduce mortality by Sudden Cardiac Death.1,14 On
the other hand, only few patients with ICD are receiving shock ther-
apy, consistent with the current study.31,32 However, the use of NAG
in daily practice requires further investigation.
6 | LIMITATIONS
This was a single-centre study of 314 patients. Patients with terminal
CKD were excluded and 84% were men. Therefore, severely ill
patients and women may be underrepresented. Hereby, we could
avoid accumulation of markers at patients without urinary elimination
on dialysis. Further, only 27 patients reached the endpoint of ade-
quate ICD shock therapy, but we should consider that only a small
number of patients with ICD receive shocks at all. The detailed cir-
cumstances of ventricular arrhythmia and ICD shock therapy were not
analysed, for example, electrolytes at the time of shock therapies
were not evaluated. Ventricular arrhythmias at a frequency
underneath the adjusted frequency for shock therapy were not con-
sidered. Nevertheless, further studies are necessary to characterize
more precisely the relationship between tubular markers and the
occurrence of ventricular arrhythmias.
The current study investigated the tubular markers NAG and
KIM-1 as well as NT-proBNP as an established marker for heart failure
in an ICD-cohort. Similar to NT-proBNP, NAG showed promising
value for overall prognostication in ICD patients. Especially, NAG
seems to incorporate an additional prognostic value regarding occur-
rence of adequate ICD shock therapies. Overall, this was the first
study to our knowledge, which reported association between tubular
markers and occurrence of ventricular arrhythmias. Therefore, further
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